Demo Data from SIGIR 2026 / reviewers in the wild / expert
Yutong Li 0006
dblp:55/10759-6
· DBLP profile ↗
2ranked-venue papers
2as first author
2since 2021 · last 2024
0000-0003-4420-4518ORCID · verified
Domains — the database's venue-derived domains; a paper can count in several
Artificial intelligence and machine learning · 1 · 1 first-author · 1 since 2021Applied, interdisciplinary, general and emerging computing · 1 · 1 first-author · 1 since 2021
Expertise — from the expertise taxonomy: the topics of the expert's papers under the CCF categories. A weight counts papers with recency: 1 for a paper about the topic, 0.3 when the topic is its context, halved every five years.
| Interdisciplinary, comprehensive, and emerging computing
1 paper |
Bioinformatics and computational biology · 100% |
Topics — the 4 heaviest of 5, each with the papers that count most for it
| Topic | Weight | Papers | Last | Evidence papers |
|---|---|---|---|---|
Bioinformatics and computational biology › drug discovery
drug design |
0.8 | 1 | 2024 | CLigOpt: controllable ligand design through target-specific optimization · Bioinform. 2024 |
Bioinformatics and computational biology › drug discovery › drug design
fragment-based drug design |
0.8 | 1 | 2024 | CLigOpt: controllable ligand design through target-specific optimization · Bioinform. 2024 |
Bioinformatics and computational biology › drug discovery › drug design
ligand design |
0.8 | 1 | 2024 | CLigOpt: controllable ligand design through target-specific optimization · Bioinform. 2024 |
Bioinformatics and computational biology › molecular informatics › cheminformatics
molecule generation |
0.8 | 1 | 2024 | CLigOpt: controllable ligand design through target-specific optimization · Bioinform. 2024 |
Methods — techniques the papers use, named apart from their topics
variational autoencoder · 0.8multi-objective optimization · 0.8molecular docking · 0.8
| Year | Publication | Venue | Position |
|---|---|---|---|
| 2024 | Optimisation-based modelling for explainable lead discovery in malariaabstractBACKGROUND: The search for new antimalarial treatments is urgent due to growing resistance to existing therapies. The Open Source Malaria (OSM) project offers a promising starting point, having extensively screened various compounds for their effectiveness. Further analysis of the chemical space surrounding these compounds could provide the means for innovative drugs. METHODS: We report an optimisation-based method for quantitative structure-activity relationship (QSAR) modelling that provides explainable modelling of ligand activity through a mathematical programming formulation. The methodology is based on piecewise regression principles and offers optimal detection of breakpoint features, efficient allocation of samples into distinct sub-groups based on breakpoint feature values, and insightful regression coefficients. Analysis of OSM antimalarial compounds yields interpretable results through rules generated by the model that reflect the contribution of individual fingerprint fragments in ligand activity prediction. Using knowledge of fragment prioritisation and screening of commercially available compound libraries, potential lead compounds for antimalarials are identified and evaluated experimentally via a Plasmodium falciparum asexual growth inhibition assay (PfGIA) and a human cell cytotoxicity assay. CONCLUSIONS: Three compounds are identified as potential leads for antimalarials using the methodology described above. This work illustrates how explainable predictive models based on mathematical optimisation can pave the way towards more efficient fragment-based lead discovery as applied in malaria. Yutong Li 0006, Jonathan Cardoso-Silva, John M. Kelly, Michael J. Delves, Nicholas Furnham, Lazaros G. Papageorgiou, Sophia Tsoka |
Artif. Intell. Medicine | 1 |
| 2024 | CLigOpt: controllable ligand design through target-specific optimizationabstractMOTIVATION: A key challenge in deep generative models for molecular design is to navigate random sampling of the vast molecular space, and produce promising molecules that strike a balance across multiple chemical criteria. Fragment-based drug design (FBDD), using fragments as starting points, is an effective way to constrain chemical space and improve generation of biologically active molecules. Furthermore, optimization approaches are often implemented with generative models to search through chemical space, and identify promising samples which satisfy specific properties. Controllable FBDD has promising potential in efficient target-specific ligand design. RESULTS: We propose a controllable FBDD model, CLigOpt, which can generate molecules with desired properties from a given fragment pair. CLigOpt is a variational autoencoder-based model which utilizes co-embeddings of node and edge features to fully mine information from molecular graphs, as well as a multi-objective Controllable Generation Module to generate molecules under property controls. CLigOpt achieves consistently strong performance in generating structurally and chemically valid molecules, as evaluated across six metrics. Applicability is illustrated through ligand candidates for hDHFR and it is shown that the proportion of feasible active molecules from the generated set is increased by 10%. Molecular docking and synthesizability prediction tasks are conducted to prioritize generated molecules to derive potential lead compounds. AVAILABILITY AND IMPLEMENTATION: The source code is available via https://github.com/yutongLi1997/CLigOpt-Controllable-Ligand-Design-through-Target-Specific-Optimisation. Yutong Li 0006, Pedro H. C. Avelar, Xinyue Chen 0009, Min Wu 0008, Sophia Tsoka |
Bioinform. | 1 |